Associations - PALB2 (Partner and localizer of BRCA2)

PALB2 mutation	Pancreatic Adenocarcinoma	PALB2 mutation	Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
PALB2 mutation	Prostate Cancer	PALB2 mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
PALB2 mutation	HER2 Negative Breast Cancer	PALB2 mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2	talazoparib Sensitive: A2 - Guideline talazoparib Sensitive : A2
PALB2 mutation	HER2 Negative Breast Cancer	PALB2 mutation	HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
PALB2 mutation	Pancreatic Adenocarcinoma	PALB2 mutation	Pancreatic Adenocarcinoma	rucaparib Sensitive: A2 - Guideline rucaparib Sensitive : A2	rucaparib Sensitive: A2 - Guideline rucaparib Sensitive : A2
PALB2 mutation	Pancreatic Adenocarcinoma	PALB2 mutation	Pancreatic Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
PALB2 mutation	Biliary Tract Cancer	PALB2 mutation	Biliary Tract Cancer	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2	PARP inhibitor Sensitive: A2 - Guideline PARP inhibitor Sensitive : A2
PALB2 mutation	Ovarian Cancer	PALB2 mutation	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
PALB2 mutation	Breast Cancer	PALB2 mutation	Breast Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
PALB2 mutation	Ovarian Cancer	PALB2 mutation	Ovarian Cancer	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B	CX-5461 Sensitive: B - Late Trials CX-5461 Sensitive : B
PALB2 mutation	Pancreatic Cancer	PALB2 mutation	Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2
PALB2 mutation	Pancreatic Cancer	PALB2 mutation	Pancreatic Cancer	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2	rucaparib Sensitive: C2 – Inclusion Criteria rucaparib Sensitive : C2
PALB2 mutation	Breast Cancer	PALB2 mutation	Breast Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
PALB2 mutation	Urothelial Cancer	PALB2 mutation	Urothelial Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
PALB2 mutation	HER2 Negative Breast Cancer	PALB2 mutation	HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
PALB2 mutation	Breast Cancer	PALB2 mutation	Breast Cancer	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2
PALB2 mutation	Triple Negative Breast Cancer	PALB2 mutation	Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
PALB2 mutation	Pancreatic Ductal Adenocarcinoma	PALB2 mutation	Pancreatic Ductal Adenocarcinoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
PALB2 mutation	Hormone Receptor Positive Breast Cancer	PALB2 mutation	Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials lenvatinib Resistant : C3	lenvatinib Resistant: C3 – Early Trials lenvatinib Resistant : C3
PALB2 mutation	Pancreatic Cancer	PALB2 mutation	Pancreatic Cancer	oxaliplatin Sensitive: C3 – Early Trials oxaliplatin Sensitive : C3	oxaliplatin Sensitive: C3 – Early Trials oxaliplatin Sensitive : C3
PALB2 mutation	Prostate Cancer	PALB2 mutation	Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3
PALB2 mutation	Pancreatic Ductal Adenocarcinoma	PALB2 mutation	Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3
PALB2 mutation	Melanoma	PALB2 mutation	Melanoma	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3	CTLA4 inhibitor Sensitive: C3 – Early Trials CTLA4 inhibitor Sensitive : C3
PALB2 deletion	Prostate Cancer	PALB2 deletion	Prostate Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
PALB2 mutation	Pancreatic Ductal Adenocarcinoma	PALB2 mutation	Pancreatic Ductal Adenocarcinoma	ipilimumab + niraparib Sensitive: C3 – Early Trials ipilimumab + niraparib Sensitive : C3	ipilimumab + niraparib Sensitive: C3 – Early Trials ipilimumab + niraparib Sensitive : C3
PALB2 deletion	Uterine Corpus Leiomyosarcoma	PALB2 deletion	Uterine Corpus Leiomyosarcoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
HR positive + BRCA1 mutation + PALB2 mutation	HER2 Negative Breast Cancer	HR positive + BRCA1 mutation + PALB2 mutation	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
HR positive + BRCA2 mutation + PALB2 mutation	HER2 Negative Breast Cancer	HR positive + BRCA2 mutation + PALB2 mutation	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Resistant : C3
PALB2 mutation	HER2 Negative Breast Cancer	PALB2 mutation	HER2 Negative Breast Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
PALB2 mutation	Endometrial Cancer	PALB2 mutation	Endometrial Cancer	rucaparib + E 3810 Sensitive: C4 – Case Studies rucaparib + E 3810 Sensitive : C4	rucaparib + E 3810 Sensitive: C4 – Case Studies rucaparib + E 3810 Sensitive : C4
PALB2 deletion	Endometrial Cancer	PALB2 deletion	Endometrial Cancer	olaparib Sensitive: C4 – Case Studies olaparib Sensitive : C4	olaparib Sensitive: C4 – Case Studies olaparib Sensitive : C4
PALB2 mutation	Triple Negative Breast Cancer	PALB2 mutation	Triple Negative Breast Cancer	carboplatin + docetaxel Sensitive: D – Preclinical carboplatin + docetaxel Sensitive : D	carboplatin + docetaxel Sensitive: D – Preclinical carboplatin + docetaxel Sensitive : D

PALB2 (Partner and localizer of BRCA2)

Associations(32)

Associations
(32)